ES2080732T3 - Derivados de hirudina con efecto retardado. - Google Patents

Derivados de hirudina con efecto retardado.

Info

Publication number
ES2080732T3
ES2080732T3 ES89109772T ES89109772T ES2080732T3 ES 2080732 T3 ES2080732 T3 ES 2080732T3 ES 89109772 T ES89109772 T ES 89109772T ES 89109772 T ES89109772 T ES 89109772T ES 2080732 T3 ES2080732 T3 ES 2080732T3
Authority
ES
Spain
Prior art keywords
hirudine
derivatives
delayed effect
delayed
effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89109772T
Other languages
English (en)
Inventor
Peter Crause
Paul Habermann
Martin Kramer
Rainer Obermeier
Klaus Sauber
Dominique Tripier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6355879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2080732(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2080732T3 publication Critical patent/ES2080732T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA INVENCION SE REFIERE A DERIVADOS DE HIRUDINA, QUE SE FORMAN DE HIRUDINA O DE SUS SALES VIABLES FISIOLOGICAS Y DE UN TRANSPORTADOR, UN PROCEDIMIENTO PARA SU OBTENCION Y SU UTILIZACION COMO INHIBIDOR DE TROMBINA.
ES89109772T 1988-06-04 1989-05-30 Derivados de hirudina con efecto retardado. Expired - Lifetime ES2080732T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3819079A DE3819079A1 (de) 1988-06-04 1988-06-04 Hirudin-derivate mit verzoegerter wirkung

Publications (1)

Publication Number Publication Date
ES2080732T3 true ES2080732T3 (es) 1996-02-16

Family

ID=6355879

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89109772T Expired - Lifetime ES2080732T3 (es) 1988-06-04 1989-05-30 Derivados de hirudina con efecto retardado.

Country Status (21)

Country Link
US (1) US5538946A (es)
EP (1) EP0345616B1 (es)
JP (1) JP2804514B2 (es)
KR (1) KR0140884B1 (es)
AT (1) ATE130315T1 (es)
AU (1) AU625215B2 (es)
CA (1) CA1340197C (es)
CY (1) CY2025A (es)
DE (2) DE3819079A1 (es)
DK (1) DK175103B1 (es)
ES (1) ES2080732T3 (es)
FI (1) FI98703C (es)
GR (1) GR3018364T3 (es)
HK (1) HK1006024A1 (es)
HU (1) HU204851B (es)
IE (1) IE72201B1 (es)
IL (1) IL90507A0 (es)
NO (1) NO177312C (es)
NZ (1) NZ229402A (es)
PT (1) PT90743B (es)
ZA (1) ZA894180B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2000887A1 (en) * 1988-11-01 1990-05-01 Cecilia S.L. Ku Thromboresistant materials and methods for making same
US5663141A (en) * 1989-12-01 1997-09-02 Basf Aktiengesellschaft Hirudin/polyalkylene glycol conjugates and hirudin muteins
JP2975632B2 (ja) * 1990-03-30 1999-11-10 生化学工業株式会社 グリコサミノグリカン修飾プロテイン
GB2247239A (en) * 1990-08-22 1992-02-26 Ciba Geigy Ag Hirudin conjugates with polyoxyethylene
DE4041185A1 (de) * 1990-12-21 1992-06-25 Knoll Ag Verwendung von hirudin und dessen muteinen zur kombinationsbehandlung von tumoren
DE4437502A1 (de) * 1993-12-02 1995-06-08 Basf Ag Hirudin-Konjugate aus Hirudin und lipophilen Verbindungen
DE4342154A1 (de) * 1993-12-10 1995-06-14 Behringwerke Ag Amidinophenylalaninderivate, Verfahren zu deren Herstellung, deren Verwendung und diese enthaltende Mittel als Antikoagulantien
DE4404168A1 (de) * 1994-02-10 1995-08-17 Hoechst Ag Hirudinderivate und Verfahren zu deren Herstellung
DE19533817C2 (de) * 1995-09-13 1999-12-09 Max Planck Gesellschaft Komplex-gebundene Hemmstoffe aktivierbarer Stoffwechselenzyme als molekulare Marker zur Diagnostik und Therapieüberwachung
US7045585B2 (en) 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
US6491965B1 (en) 1995-11-30 2002-12-10 Hamilton Civic Hospitals Research Development, Inc. Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US6562781B1 (en) 1995-11-30 2003-05-13 Hamilton Civic Hospitals Research Development Inc. Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US5856452A (en) 1996-12-16 1999-01-05 Sembiosys Genetics Inc. Oil bodies and associated proteins as affinity matrices
DE19915862A1 (de) * 1999-04-08 2000-10-12 Max Planck Gesellschaft Verwendung von molekulargewichtserweitertem Hirudin als Antikoagulans bei der extrakorporalen Nierenersatztherapie
US6809076B2 (en) * 2000-03-20 2004-10-26 Abbott Gmbh & Co. Kg Use of anticoagulant agents in the extracorporeal treatment of blood
US6818392B2 (en) 2000-12-06 2004-11-16 Abbott Laboratories Monoclonal antibodies to human immunodeficiency virus and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55500091A (es) * 1978-02-17 1980-02-14
DE2930542A1 (de) * 1979-07-27 1981-02-12 Hoechst Ag Neue insulinderivate und verfahren zu ihrer herstellung
DE3586333T2 (de) * 1984-03-27 1992-12-10 Transgene Sa Expressionsvektoren fuer hirudin, transformierte zellen und verfahren zur herstellung von hirudin.
US4666884A (en) * 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
DE3438296A1 (de) * 1984-04-18 1985-11-07 Hoechst Ag, 6230 Frankfurt Neue polypeptide mit blutgerinnungshemmender wirkung, verfahren zu deren herstellung bzw. gewinnung, deren verwendung und diese enthaltende mittel
DE3583361D1 (de) * 1984-06-14 1991-08-08 Ucp Gen Pharma Ag Verfahren zur herstellung von thrombin-inhibitoren.
DE3429430A1 (de) * 1984-08-10 1986-02-20 Hoechst Ag, 6230 Frankfurt Gentechnologisches verfahren zur herstellung von hirudin und mittel zur durchfuehrung dieses verfahrens
DE3500268A1 (de) * 1985-01-05 1986-07-10 Hoechst Ag, 6230 Frankfurt Praeparate mit verzoegerter wirkung, verfahren zu deren herstellung sowie entsprechende mittel zur human- bzw. veterinaermedizinischen anwendung
DE3506992A1 (de) * 1985-02-27 1986-08-28 Plantorgan Werk Heinrich G.E. Christensen, KG, 2903 Bad Zwischenahn Modifizierte hirudine, verfahren zu deren herstellung und pharmazeutische mittel, die diese wirkstoffe enthalten
FR2593518B1 (fr) * 1985-05-02 1989-09-08 Transgene Sa Vecteurs d'expression et de secretion de l'hirudine par les levures transformees
EP0209061B1 (de) * 1985-07-17 1994-01-12 Hoechst Aktiengesellschaft Neue Polypeptide mit blutgerinnungshemmender Wirkung, Verfahren zu deren Herstellung bzw. Gewinnung, deren Verwendung und diese enthaltende Mittel
DE3541856A1 (de) * 1985-11-27 1987-06-04 Hoechst Ag Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens

Also Published As

Publication number Publication date
HU204851B (en) 1992-02-28
NO177312B (no) 1995-05-15
NO892267D0 (no) 1989-06-02
HK1006024A1 (en) 1999-02-05
US5538946A (en) 1996-07-23
DK270789D0 (da) 1989-06-02
NO892267L (no) 1989-12-05
IE891815L (en) 1989-12-04
ZA894180B (en) 1990-02-28
KR910001041A (ko) 1991-01-30
PT90743B (pt) 1994-10-31
FI892686A0 (fi) 1989-06-01
DE3819079A1 (de) 1989-12-07
DK270789A (da) 1989-12-05
IE72201B1 (en) 1997-04-09
EP0345616A2 (de) 1989-12-13
CA1340197C (en) 1998-12-15
DE58909493D1 (de) 1995-12-21
HUT51298A (en) 1990-04-28
IL90507A0 (en) 1990-01-18
EP0345616B1 (de) 1995-11-15
ATE130315T1 (de) 1995-12-15
GR3018364T3 (en) 1996-03-31
JPH0267300A (ja) 1990-03-07
FI892686L (fi) 1989-12-05
EP0345616A3 (de) 1991-03-20
FI98703C (fi) 1997-08-11
AU625215B2 (en) 1992-07-02
NZ229402A (en) 1992-05-26
CY2025A (en) 1998-02-20
JP2804514B2 (ja) 1998-09-30
DK175103B1 (da) 2004-06-01
AU3595589A (en) 1989-12-07
KR0140884B1 (ko) 1998-06-15
FI98703B (fi) 1997-04-30
PT90743A (pt) 1989-12-29
NO177312C (no) 1995-08-23

Similar Documents

Publication Publication Date Title
ES2114870T3 (es) Nuevos derivados de mercaptoacetilamida utiles como inhibidores de encefalinasa y eca.
ES2054860T5 (es) Derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion y su utilizacion como medicamentos.
ES2053778T3 (es) Procedimiento para la obtencion de derivados del tiazol.
NO923744D0 (no) Nye 2-substituerte indan-2-mercaptoacetylamidderivater anvendbare som inhibitorer av enkefalinase og ace
ES2072959T3 (es) Derivados de aminoacido.
DE69214397D1 (de) 2-Substituierte Indane-2-Carboxyalkyl-Verbindungen mit Enkephalinase und ACE-Hemmwirkung
ES2159798T3 (es) Derivados heterociclicos como inhibidores de la agregacion plaquetaria.
NO942994L (no) Aminoacetylmercaptoacetylamidderivater som er anvendbare som inhibitorer av enkefalinase og ACE
MX9306758A (es) Derivados novedosos mercaptoacetilamida de lactama biciclica, utiles como inhibidores de la encefalinasa y eca.
AR240824A1 (es) Procedimiento para preparar derivados de 3-propenil-cefalosporinas, que poseen configuracion (z) con respecto al doble enlace exociclico y sus sales farmaceuticamente aceptables
MX9306023A (es) Acidos quinoloncarboxilicos y procedimiento para su obtencion.
DK248378A (da) 1-(2-phenylethyl)-triazolium-salte fremgangsmaade til fremstilling deraf samt disses anvendelse som fungcider
GT199900173A (es) Derivados de mononitrato de isosorbida y su empleo como agentes vasodilatadores con tolerancia disminuida.
ES2043665T3 (es) 6,11-dihidro-11-(4-piperidiliden)-5h-benzo-(5,6)-ciclohepta-(1,2-b)-piridinas y composiciones y metodos de uso.
PT90743A (pt) Processo para a preparacao de derivados de hirudina com accao retardada e de composicoes farmaceuticas que os contem
MX9206563A (es) Utilizacion de derivados de anfotericina b como inhibidores de proteasas.
FI950842A0 (fi) Enkefalinaasin inhibiittoreina käyttökelpoisia uusia 2-substituoituja trisyklisiä indaani-2-merkaptoasetyyliamidijohdannaisia
ES2019554A6 (es) Procedimiento para preparar n,n -ditrimetoxibenzoilpiperazinas sustituidas en posicion 2"
AR224610A1 (es) Procedimiento para obtener derivados,de acidos benzacil-benzimidazol-2-carboxilicos o de 2-hidroximetilo y sus sales
ES2042726T3 (es) Beta-alquilmelatoninas.
ES504879A0 (es) Procedimiento para la preparacion de derivados fluorados de alquinilano-diamina que son inhibidores de enzimas de oecarboxilasa
ES465861A1 (es) Procedimiento de preparacion de 4-difenilmetilen-1-hidroxi- bencil-piperidinas.
ES2036533T3 (es) Derivados de 1,6-naftiridina, procedimientos para su obtencion y de medicamentos que los contienen para el tratamiento de enfermedades de los vasos sanguineos.
ES2058181T3 (es) Procedimiento para la obtencion de esteres del acido 5-formil-valerico.
ES2103131T3 (es) Nuevos agentes de nucleosido carbociclico utiles como inhibidores selectivos de citoquinas proinflamatorias.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 345616

Country of ref document: ES